Diabetes

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

Accuracy of data recorded with the GlucoBeam was found to be comparable to standard finger-stick blood glucose tests.

The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Your daily dose of the clinical news you may have missed.

Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.

The 30-year program has tracked and compiled data on diabetes prevention, treatment, and outcomes, providing a foundation and insights for international research.

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.